Drug Trial Radar · NCT06601192
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jul 15, 2024
Primary completion
Feb 2, 2025
Study completion Feb 25, 2025
Sponsor
- Lead sponsor
- Enanta Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
Conditions
- RSV Infection
- QTc Interval
Interventions
zelicapavir (therapeutic dose)Drug
Subjects will receive zelicapavir (TD) once per treatment period.
zelicapavir (supratherapeutic dose)Drug
Subjects will receive zelicapavir (SD) once per treatment period.
PlaceboDrug
Subjects will receive zelicapavir matching placebo once per treatment period.
moxifloxacinDrug
Subjects will receive moxifloxin once per treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction QTcF (ΔΔQTcF) after TD and SD of ZelicapavirTime frame: Up to 24 hours post dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
ICON
Lenexa, Kansas
ICON Early Phase, LLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.